Angel Investors
Angels are a critical component of investment activity among certain types of SBIR firms. Further, their expertise and network of contacts can be invaluable to younger, smaller firms. Reflecting this, several active Angel Investors will participate on this occasion. These include:
  • Adi R Guzdar
    		•
  • Daniel Ross
    		•
  • John J (Jay) Schwartz
    		•
  • SBIR Awardees: presenters
    		•
  • VC Investors: list
    		•
    In this context, Participants are those firms - both SBIR Awardees and Investors - whose representatives will be featured in that working part of this Event focused to VC-Investment Presentations.  Complete as of today's date, participating VCs will be posted here once their full status has been confirmed.
    To set this effort in context, it should be noted that quite remarkable Forty-Nine well-known VC entities are invested in Ten or more SBIR firms, the most active being
    • Alta Partners with 38 SBIR investments
    • Oxford Biosciences with 32
    • Arch Ventures and SR One Limited, with 31 each
    • Venrock with 28
    Among smaller funds, those with early-stage investment and/or specialist focus, the total number of investments may be smaller. However, in many such firms SBIR Awardees are a substantial percentage of the portfolio. In the Harris & Harris Group, for example, a well-known investor in the nanotech space, a full two-thirds of their portfolio are SBIR-involved firms.
    With strong emphasis on engaging those in the right industry space, in the mix of invited Funding sources representatives are targeted from:
    • 'traditional' Financial - with both early and later stage investment focus, very large and smaller funds
    • what would classically be considered Corporate VC.
    • a few of the organized Angel Investors groups
    • and a couple of experienced state- and regional-focused entities.
    Between them these players offer an investment profile interest that encompasses early-stage through later rounds and covers the range of technology and industry focus. What all invited VCs to this event hold in common is that they are already actively invested in SBIR-involved firms.

    Personal invitations:
    Critically important in making this Event work are the in-person invitations extended to those Funds which have a significant number of SBIR involved firms in their portfolio - see box above. When contact is made, most are responding.  With quality deal flow always an issue in the VC business, they know a useful opportunity when they see one.

    Let's be very clear -- SBIR is almost certainly not the primary reason for investment decisions. However, from discussions with many SBIR-active VCs, it is apparent that program participation is commonly viewed a positive factor in that process. They understand the effectiveness of SBIR participation in enhancing the down-stream valuation of their investment. For these investors, the SBIR community represents an important pool of talent and business opportunity.

    Today's date: 03/10/2010
    Investor Listing
    Number of Funding Sources: 23
    Number of Participating People: 31
    Venture Capital Firm
    Description
    3i
         		3i is active across all stages of funding. From early-stage venture capital to growth capital and buyouts, 3i invests €1.3bn a year in some of the most exciting and ambitious companies in the world Dedicated to value creation, the firm’s purpose is substantially to increase the value of our portfolio companies and then to realize this value, both for ourselves and for our partners. 3i's international relationship network is unique with over 250 investment professionals spanning three continents, linking us to a wealth of corporate contacts and industry experts and giving us both a local and global view of industry trends. It also means we have the scale, the agility and the talent needed to deliver even the most challenging deals.
    Arrowhead Research Corporation Arrowhead Research Corporation is a venture-funding, nanotechnology-focused company structured to bring together a diverse set of technologies, a broad suite of intellectual property, and quality personnel. There are three strategic components to Arrowhead's business model: * The Commercialization Program - Arrowhead forms or acquires majority-owned subsidiary companies pursuing products based on nanotechnology in high growth technology markets. * R&D Pipeline - Arrowhead funds nanoscience research at universities in exchange for the exclusive right to license the technology. * The IP Toolbox - Arrowhead acquires, licenses, and sublicenses intellectual property in nanotechnology.
    Astellas Venture Management Originally established as Yamanouchi Venture Capital in 2000, Astellas Venture Capital LLC (AVC) is focused to biotech investment. The parent company of AVC is Astellas Pharma Inc., headquartered in Tokyo. Created in April 2005, by the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd, Astellas Pharma Inc is one of the top pharmaceutical companies in Japan. Yamanouchi has excelled in the fields of urology, gastroenterology and cardiovascular medicine, while Fujisawa has had a strong franchise in the fields of immunology/inflammation, infectious disease and CNS. The combined strengths of Yamanouchi and Fujisawa provide Astellas with a unique and highly competitive edge.
    Bantam Group, Common Angels, Walnut Group The Bantam Group invest in emerging technology companies. Prefer the active involvement that can be key building the company. Novel technologies will be considered, as are troubled situations. Transaction can range from $10,000 to $1 Million. ** CommonAngels is a group of 50 private investors and three dozen limited partners in a co-investment fund. Work closely with early-stage software, information technology and Internet companies. Investments range $250,000-$2,000,000. ** Walnut Venture Associates: experienced entrepreneurs-investors focused on New England-based, information technology companies in rapidly growing markets. Invest at any stage but prefer seed-stage, first round, or recapitalizations. Can commit to $1,000,000. We are also LPs in a number of venture partnerships - partly to diversify our portfolio, but primarily to maintain ongoing relationship with these funds. Deal share co-invest.
    Boston Millennia Partners Boston Millennia Partners provides private equity financing to high growth companies in the healthcare, life sciences, telecommunications, and information technology industries. Our team brings over one hundred years of combined private equity experience to the investment process. Our broad experience, combined with expertise in finance; operations; engineering; life sciences research and development; partnering with pharmaceutical companies; business development; executive recruiting; and law provides significant value to the companies in which we invest. The growth and success of our portfolio companies have, in turn, allowed us to grow and expand our capital base to over $700 million.
    Commons Capital Commons Capital LP is a new venture capital fund seeking strong financial returns as well as significant social and environmental impact. Investment is made in "double bottom-line" early-stage companies whose products, services or corporate cultures promote a sustainable economy by delivering market solutions to major social and environmental challenges. The fund is affiliated with Investors’ Circle, a national network of high net-worth individuals and venture funds investing in "double bottom-line" entrepreneurs. Commons has access to the Circle’s deal flow and the networks of its 120 members, who include professional investment managers and former entrepreneurs. Investment is in the following areas: * Clean energy * Environment * Education * Healthcare
    Harris & Harris Group Inc Harris & Harris Group concentrates its new business activities exclusively in a single focus: tiny tech, including nanotechnology, microsystems and microelectromechanical systems (MEMS) technology.
    Homeland Venture Partners LP Homeland Venture Partners, LP, is a $100 million private equity firm in formation focused on the high technology startup and emerging companies serving the markets for: * Homeland Defense--Government and Commercial * Network Security and Cyber Security * Asymmetric Warfare (Anti-Terrorism) * Special Operations Warfare * Department Of Defense Force Transformation* Intelligence Communities
    Hub Investment Group, LLC Organized to match active, early stage investors with technology-driven, start-up companies, the Hub Angel group is focused on the greater Boston area - known as the "Hub" by Boston locals. With now more than 50 Members in Hub Fund I and Hub Fund II and investing across industry sectors, the Group provides co-investment rights for the individual Members of the Fund. To date, Hub has invested in 12 companies including financial services, entertainment, retail, biotechnology, healthcare, water treatment, food technology, and digital audio to a total of more than $10 million. Co-investors with Hub include GE Capital, Commonwealth Capital, Rock Maple, Brook, Thomas Weisel, Fidelity, Boston Community Ventures, Bessemer, Blue Chip, Blue Sky, and FlagShip
    Lux Capital Lux Capital is a research-driven investment firm, credited with introducing the first investment framework for nanotechnology. During the dot.com era, Lux held a contrarian position, seeing opportunity in the neglected fields of material science and mesoscale physics and their intersection with other scientific disciplines -- later referred to as “nanotechnology”. Grounded in original research, interviews, and site visits to leading universities, the firm’s principals identified nanotechnology as a nascent field substantiated by a growing pace of scientific breakthroughs and government funding. Lux instituted a plan to cultivate key academic and industry relationships, build credibility, and become an industry leader at the epicenter of all activity within nanotechnology. Lux Capital is credited with having introducing the first investment framework for nanotechnology adopted by other venture capital funds and top-tier Wall Street investment banks, leading to relationships with leading private-equity firms and investment banks that serve as sources of syndicate investment partners, follow-on financing, and exit opportunities for the entrepreneurs we invest in.
    MA Green Energy Fund The Massachusetts Green Energy Fund invests in a broad range of emerging power generation technologies, including photovoltaics, fuel cells, hydrogen storage, hydrogen generation, wind, wave, tidal, biomass, biodiesel, power control, power conditioning, engine design, and energy management and storage technologies.
    Massachusetts Technology Development Corporation (MTDC) Established in 1978, Massachusetts Technology Development Corporation - MTDC - a leading-edge venture capital firm addressing specifically the Established in 1978 as the first public-sector,state-focused VC Fund, the Massachusetts Technology Development Corporation (MTDC) is a leading-edge venture capital firm specifically addressing the "capital gap" for MA-based start-up and expansion of early-stage technology companies. MTDC has invested in many of Massachusetts' most promising new technology-based firms. Though initial investments can be up to $500,000, most are in the $250K-$500Krange. Investments are made primarily as equity with the normal rights and privileges accorded shareholders and other co-investors. MTDC may also offer long-term, unsecured, subordinated debt.
    Mohr Davidow Ventures MDV invests in innovative entrepreneurs with deep expertise in energy and materials, Internet services; life sciences, semiconductor and software and systems. Our venture capital team engages very early in the life of a company to impact its long-term success. We apply years of real-world experience to accelerate each company's time to market and optimize its success. For more than 20 years, our mission as an early stage venture capital firm has been to identify, invest in, mentor and develop venture-backed companies that redefine how organizations and individuals apply new technologies and scientific advances.
    Motorola Ventures Motorola Ventures is focused on opportunities that complement Motorola’s total business strategy. We evaluate "new idea companies," the people and technologies behind them and the vision they bring. We identify cutting-edge technology investments that will help us to achieve the best solutions to fit our customers' needs. Every investment is a strategic alliance that fulfills a Motorola Ventures profile while also demonstrating a defensible intellectual property position, a proven business model, customer interest and a reasonable time to profit. Typical investment is $3M-$5M along with the resources required to nurture a venture company through the critical phases of start-up, growth and expansion by offering business and technology expertise, market leadership and brand recognition to growing companies.
    Navigator Technology Ventures Navigator Technology Ventures usually lead or co-lead a first round of investment. In addition to starting and investing in early-stage ventures, Navigator understands and manages the critical path to validating the viability of a commercial concept. Navigator takes an active role and board seat in embryonic companies and provide the company founders with the services and advocacy that they need to accelerate the establishment of value throughout the lifetime of the venture. This acceleration of value creation translates into greater returns for the innovator in the long run
    Norwich Ventures Norwich Ventures invests exclusively in the medical device industry.Norwich Ventures is a venture capital firm committed to helping entrepreneurs, healthcare professionals and inventors build innovative medical device companies. We invest early in a company's life, often when it is just an idea. We are healthcare entrepreneurs ourselves and work as a team to bring our experience, industry expertise and network to every company we support. We believe top-caliber support and guidance, not capital, is of greatest value to emerging companies.
    Paladin Capital Group Paladin is an established, multi-stage private equity firm investing in growing companies through acquisitions and expansion capital. Headquartered in Washington D.C., with offices in New York City, NY and Atlanta, GA, Paladin has approximately half a billion dollars under management across two distinct funds. Paladin established its first fund in 2001 and launched the $235M Homeland Security Fund in 2004. Paladin’s Homeland Security Fund invests in companies with products and services that address homeland security issues and needs. Specifically, the fund looks companies with existing solutions capable of having an immediate impact on preventing , defending , coping and/or recovering from threats to the nation's critical infrastructure and to homeland security. With focus on infrastructure assurance, portfolio companies include enterprises focused on identity management, antimicrobial solutions, mesh networks, IT services, data storage, business process software, network management software and detection. The Partners' Fund is an opportunistic private equity fund primarily targeting growing, small to mid-sized companies who are market leaders in their industry segment. Targeted industry sectors include industrial manufacturing , educational services, energy/environment, healthcare services, financial services, and industrial manufacturing, among others
    RockPort Capital Partners RockPort Capital Partners is focused to investing in and supporting the most promising entrepreneurs and technologies in the Energy and Power, Advanced Materials, and Process and Prevention sectors often described as “Cleantech” or “Energy Tech”. RockPort in fact defines its investment mandate and targets of opportunity more broadly than the standrd definition of these areas. Where new technologies enabled by revolutionary advances in basic physical sciences approached from an interdisciplinary framework, offer value propositions previously unavailable to business in these sectors, the firm will be interested. Depending on stage and risk profile, the firm may initially invest between $1 million and $10 million and are willing to be the lead, or co-investor in deals ranging from $5 million to $50 million. Due to the time we spend with each of our investments, we prefer to hold a significant ownership in portfolio companies and typically become a member of the Board of Directors.
    SV Life Sciences SV Life Sciences™ ('SVLS'), known previously as Schroder Ventures Life Sciences invest in companies requiring funding within the human life sciences sector including biotechnology and pharmaceuticals, medical devices and instruments, healthcare IT and services. Established in 1993, with offices in Boston, London and San Francisco, SVLS advises or manages four funds with total capital of approximately $900m which invest in life science companies at all stages of development. Three of the funds are venture capital limited partnerships which provide seed, start-up, early stage and expansion capital primarily to private companies in North America and Europe. The most recently raised fund, SV Life Sciences Fund III (ILSF III), closed in 2003 with total commitments of $402m. Typical investment size for these funds is between $2m and $20m. The fourth fund International Biotechnology Trust plc is a publicly quoted investment trust listed on the London Stock Exchange (ticker IBT), with total net asset value of approximately $99m (£56m as at 1 October 2005). IBT has an investment focus on later stage private and smaller cap listed life sciences stocks and typical investment size is $1 to $4m.
    Synchrony Venture Management Synchrony Venture addresses the growing importance of private, venture-backed early-stage companies in the critical process of producing and commercializing innovation.
    Tokyo Boeki Tokyo Boeki is a specialized international trading company with annual global sales over $600 million. We pursue long-lasting relationships with U.S. companies looking to expand into the Japanese market. We actively seek innovative products, technologies and business development opportunities through agents agreements, joint ventures, licensing or distribution in the following fields: *Utilities, *Building materials and Refractories, *Energy, *Manufacturing Equipment, *Transportation(Automobile, Rail), *Petrochemical, *Environmental (Air, Water, Hazardous Waste), *Steel. Established in 1947 and based in Tokyo with offices worldwide, Tokyo Boeki is the experienced full-service organization you need. If you are ready to access the Japanese market, contact Mr. Kevin Lewis at our New York office.
    Vista Ventures Vista Ventures is a venture capital firm focusing on investments in early and growth-stage technology companies.
    Zero Stage Capital Zero Stage Capital is a venture capital firm that invests in emerging growth companies in the following technology sectors: information technology, communications, life sciences, and energy technology.